Concord Biotech’s IPO to open on 4th August, 2023

The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.

Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy

Fluor awarded more than $1 billion in life sciences contracts

Contracts are related to a $487 million biotech expansion project in Denmark and first phase of a new life sciences production facility valued at $574 million in Central U.S.

Biogen to acquire Reata Pharmaceuticals

Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth

USFDA accepts biologics license application for GC Biopharma's GC5107B

New products and nutraceuticals added under Jan Aushadhi Pariyojana

The product basket increased to 1800 medicines and 285 Surgical Equipment

Govt. exhorts doctors to prescribe generic gedicines

More than 9600 Pradhan Mantri Bhartiya Janaushadhi Kendras have been set up covering all districts of the country to promote generic medicines at affordable prices

AiMeD expresses dismay over FICCI’s ‘Un-Make in India’ drive

Unfortunate to see PM’s ‘Make in India’ dream being bulldozed

Dr. Reddy's Laboratories Q1 FY2024 consolidated PAT jumps to Rs. 1402.5 Cr

The company has reported total income of Rs. 6738.4 crores during the period ended June 30, 2023

Astec LifeSciences posts consolidated Q1FY24 loss at Rs. 8.19 Cr

Astec LifeSciences has reported total income of Rs. 144.55 crores during the period ended June 30, 2023